GLOW 70MG

Description

GLOW 70mg research peptide blend — Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

GLOW is a name, and the batch report is what gives it content: three synthetic peptides in one lyophilized vial — the copper tripeptide GHK-Cu, the gastric pentadecapeptide BPC-157, and TB-500, which in this batch the laboratory identified as full-length thymosin β4. Each has its own animal and cell-culture literature; the mixture has none. Supplied for laboratory research only.

Full research overview, study table & references → GLOW in Canada: research guide (component guides: BPC-157 · TB-500 · GHK-Cu)

Identity at a glance

This batch: certificate of analysis

Product tested	GLOW, declared 70 mg (this listing)
Testing laboratory	Janoshik Analytical (independent)
Report number	#172067
Sample received / analysis date	3 June 2026 / 18 June 2026
Components measured	GHK-Cu 51.15 mg · BPC-157 10.03 mg · TB-500 (TB4) 10.21 mg
Purity	Not stated on this report. The document gives identity and quantity per component only.
Report	View the report image · COA library

We print what the report states and nothing more. The three amounts sum to 71.39 mg against a 70 mg declaration (our arithmetic). Match the batch on your label to this report; the blend COA guide shows how to check a multi-component document line by line.

What researchers have looked at

• GHK-Cu, fibroblast culture (1988): collagen synthesis rose from about 10⁻¹² M and peaked at 10⁻⁹ M with no change in cell number^[1]. Rat wound chambers (1993): concentration-dependent increases in dry weight, DNA, collagen and glycosaminoglycans, with collagen I and III mRNA up and TGF-β mRNA unchanged^[2].
• GHK-Cu, rat ACL reconstruction (2015): less knee laxity and stiffer grafts at 6 weeks, but no difference from saline at 12 weeks once injections stopped^[3].
• BPC-157, rat Achilles (2003): higher failure load and better function after transection versus saline^[4]. Thymosin β4, rat wounds (1999): re-epithelialisation up 42% at day 4 and 61% at day 7^[5].
• Limits: the only combination study (BPC-157 + TB-500, 32 rats, 2026) found no added benefit over either peptide alone^[6]; a 2025 systematic review of BPC-157 found no clinical safety data^[7]; nothing tests the three-way blend, and no human study supports any use of GLOW.

Storage and handling

• Sealed lyophilized powder: −20 °C for long-term storage (site guidance: up to 24 months); cool, dry and dark short-term; no freeze–thaw cycling.
• Water-soluble components; the rat studies above used saline^{[2, 4]}. Bacteriostatic water is stocked separately. Protocols are the researcher’s own and are not published here.

Related: KLOW 80MG (adds KPV; its TB-500 is the 889 Da fragment) · GHK-CU 100MG · BPC-157 5MG · TB-500 5MG. Ships inside Canada by Canada Post; dispatch cut-off and the free-shipping threshold are in the shipping policy. The full catalogue is on our buy peptides online in Canada page.

Frequently asked questions

Can I buy GLOW 70mg in Canada?

Yes. This vial ships from inside Canada by Canada Post, with no customs hold. It is supplied for laboratory research only; none of its three components has an approved drug product in Canada, the US or the EU.

What exactly is in this GLOW batch?

Janoshik report #172067 (analysis 18 June 2026) lists GHK-Cu 51.15 mg (45.26 mg GHK plus 5.89 mg copper), BPC-157 10.03 mg and TB-500 10.21 mg, with the TB-500 line labelled TB4 (full-length thymosin β4). Those figures come from the report, not from the product name.

Why is no purity percentage shown for GLOW?

Because the batch report does not contain one. Report #172067 provides identity and per-component quantity only, so this page does not quote a purity figure. If a future report includes purity, the page will be updated to state it.

How should the GLOW blend be stored and handled?

As sealed lyophilized powder at −20 °C for the long term (the site states up to 24 months), cool, dry and dark for short periods, with no repeated freeze–thaw. Once dissolved it is a three-analyte sample; resolving the components is the researcher’s method work. No dosing or administration guidance is given.

Cited

1. Maquart et al. (1988), FEBS letters — PMID 3169264
2. Maquart et al. (1993), The Journal of clinical investigation — PMID 8227353
3. Fu et al. (2015), Journal of orthopaedic research : official publication of the Orthopaedic Research Society — PMID 25731775
4. Staresinic et al. (2003), Journal of orthopaedic research : official publication of the Orthopaedic Research Society — PMID 14554208
5. Malinda et al. (1999), The Journal of investigative dermatology — PMID 10469335
6. Biçer et al. (2026), Joint diseases and related surgery — PMID 42542926
7. Vasireddi et al. (2025), HSS journal : the musculoskeletal journal of Hospital for Special Surgery — PMID 40756949

For laboratory research use only. Not for human or animal consumption. No dosing, administration or protocol information is provided, and nothing here is a claim of efficacy or safety in humans.